. . "Bupranolol"@en . . "Bupranolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension."@en . . "Kunz, W., Jacobi, H., Koch, C. and Geus, R.J.; U.S. Patent 3,309,406; March 14, 1967."@en . . . "76%"@en . . . " "@en . . . "Quickly and completely absorbed from the gut with less than 10% oral bioavailability."@en . . . . "Bupranolol"@en . . . "Bupranolol hcl"@en . "Bupranolol is a non-selective beta blocker without intrinsic sympathomimetic activity (ISA), but with strong membrane stabilizing activity. Its potency is similar to \"propranolol\":http://www.drugbank.ca/drugs/DB00571."@en . . "23284-25-5"@en . . . "Humans and other mammals"@en . . . . "KL-255 [as hydrochloride]"@en . "2-4 hours"@en . . . "Symptoms of overdose include bradycardia, cardiac failure, hypotension, and brochospasm. "@en . . . " "@en . . . "b-1312 [As hydrochloride]"@en . . "approved"@en . . . . . . . "Bupranol"@en . . "Used to manage hypertension and tachycardia. Also used to treat glaucoma."@en . . .